Symlin Dose Escalation Efficacy vs. Conventional Therapy in Type 2 Diabetes Mellitus.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2012
At a glance
- Drugs Pramlintide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Oct 2011 Planned End Date changed from 1 May 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 16 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.